AURA Insider Trading Activity and SEC Form 4 Filings
AURA insider trading summary
Over the past 12 months, insiders at Aura Biosciences, Inc. (AURA) reported 12 sales worth $79.0M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $79.0M.
Latest AURA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Anthony S Gibney | See Remarks | Sell | $82K (12,824 @ $6.42) |
| May 7, 2026 | Matrix Capital Management Company, LP | 10% Owner | Sell | $39.0M (6,922,870 @ $5.64) |
| May 7, 2026 | David E. Goel | 10% Owner | Sell | $39.0M (6,922,870 @ $5.64) |
| Apr 16, 2026 | Conor Kilroy | See Remarks | Sell | $82K (11,738 @ $7.02) |
| Feb 17, 2026 | los Pinos Elisabet de | See Remarks | Sell | $241K (47,648 @ $5.06) |
| Feb 17, 2026 | Conor Kilroy | See Remarks | Sell | $61K (12,079 @ $5.05) |
| Feb 17, 2026 | Janet Jill Hopkins | Chief Medical Officer | Sell | $103K (20,401 @ $5.06) |
| Feb 17, 2026 | Amy Elazzouzi | Senior Vice President, Finance | Sell | $43K (8,549 @ $5.06) |
| Feb 17, 2026 | Mark Plavsic | Chief Technology Officer | Sell | $80K (15,890 @ $5.05) |
| Jan 20, 2026 | Amy Elazzouzi | Senior Vice President, Finance | Sell | $8K (1,581 @ $4.86) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.